LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that its hospital-based products business, Abraxis Pharmaceutical Products (APP), has launched Doxorubicin Hydrochloride Injection, USP 2mg/mL, the generic equivalent of Adriamycin® PFS which is owned by Bedford Laboratories, a division of Boehringer Ingelheim GmbH. According to IMS, sales in 2006 of doxorubicin hydrochloride injection in the United States exceeded $30 million. Contracts for this product have already been secured and APP expects to immediately commence marketing of Doxorubicin, which is commonly used in the treatment of a wide range of cancers. The product is AP rated, preservative-free and latex-free.
